13F reference period
Q3 2026
Security Snapshot
20/20 Biolabs, Inc. - Common Stock, par value $0.01 (AIDX) Institutional Ownership
CUSIP: 90138K101
13F Institutional Holders and Ownership History from Q1 2026 to Q3 2026
Institutions Reporting
7
Shares (Excl. Options)
175.06K
Full value: 175,059 · shares · 30 Sep 2026Price
$0.44
The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.01
- Symbol
- AIDX on Nasdaq
- All holders as of 30 Sep 2026
- Q3 2026
- Total 13F shares
- 175,059
- Total 13F value
- $76,454
- Portfolio coverage rank
- 0%
- Share change
- +10,252
- Value change
- +$4,466
- Number of holders
- 7
- Shares outstanding
- 10,340,714
- SEC-reported price per share
- $0.35
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- AIDX - 20/20 Biolabs, Inc. - Common Stock, par value $0.01 is tracked under CUSIP 90138K101.
- 7 institutions reported positions in Q3 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 15 to 7 between Q2 2026 and Q3 2026.
- SEC-reported value moved from to
$297.12K
Full value: $297,121 · USD · 30 Jun 2026.$76.45K
Full value: $76,454 · USD · 30 Sep 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 7 institutions filings for Q3 2026.
Security key
90138K101
13F reference period
Q3 2026
13F holders
7
13D/G owners
3
CIK / CUSIP context first
Open Q3 2026 holders
AIDX full holder history
20/20 Biolabs, Inc. SEC filings
20/20 Biolabs, Inc. company facts
20/20 Biolabs, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 90138K101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
AIDX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Cohen Jonathan M | 17% | 1,833,750 | Jonathan M Cohen | 03 Mar 2026 | ||||
| Full Succeed International Ltd | 6.3% | 651,465 | Full Succeed International Limited | 19 Feb 2026 | ||||
| Streeterville Capital LLC | 9.9% | 543,680 | Streeterville Capital LLC | 25 Feb 2026 |
As of 30 Sep 2026,
7
institutional investors reported holding
shares of
20/20 Biolabs, Inc. - Common Stock, par value $0.01 (AIDX).
This represents
1.7%
of the company’s total
outstanding shares.
175.06K
Full value: 175,059 · shares · 30 Sep 202610.34M
Full value: 10,340,714 · shares · Stored outstanding share countQuarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
3
Headline period
Q3 2026
Rows shown
1-3 of 3